92 related articles for article (PubMed ID: 9630477)
21. Turning behavior after unilateral lesion of the subthalamic nucleus in the rat.
Kafetzopoulos E; Papadopoulos G
Behav Brain Res; 1983 May; 8(2):217-23. PubMed ID: 6683098
[TBL] [Abstract][Full Text] [Related]
22. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats.
Manzanares J; Corchero J; Fuentes JA
Brain Res; 1999 Aug; 839(1):173-9. PubMed ID: 10482810
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation.
Izzo AA; Fezza F; Capasso R; Bisogno T; Pinto L; Iuvone T; Esposito G; Mascolo N; Di Marzo V; Capasso F
Br J Pharmacol; 2001 Oct; 134(3):563-70. PubMed ID: 11588110
[TBL] [Abstract][Full Text] [Related]
24. Effects of intrastriatal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system.
Sañudo-Peña MC; Force M; Tsou K; Miller AS; Walker JM
Synapse; 1998 Oct; 30(2):221-6. PubMed ID: 9723792
[TBL] [Abstract][Full Text] [Related]
25. Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus.
Miller AS; Walker JM
Eur J Pharmacol; 1998 Jul; 352(2-3):199-205. PubMed ID: 9716355
[TBL] [Abstract][Full Text] [Related]
26. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice.
Collins DR; Pertwee RG; Davies SN
Br J Pharmacol; 1995 Jul; 115(6):869-70. PubMed ID: 7582512
[TBL] [Abstract][Full Text] [Related]
27. Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats.
Arnold JC; Hunt GE; McGregor IS
Life Sci; 2001 Nov; 70(1):97-108. PubMed ID: 11764010
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid-induced working memory impairment is reversed by a second generation cholinesterase inhibitor in rats.
Braida D; Sala M
Neuroreport; 2000 Jun; 11(9):2025-9. PubMed ID: 10884065
[TBL] [Abstract][Full Text] [Related]
29. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Rubino T; Viganò D; Massi P; Parolaro D
J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
[TBL] [Abstract][Full Text] [Related]
30. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
31. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T; Ueno S; Obara Y; Nakahata N
J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
[TBL] [Abstract][Full Text] [Related]
32. A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia.
Eberle-Wang K; Lucki I; Chesselet MF
Neuroscience; 1996 May; 72(1):117-28. PubMed ID: 8730711
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla.
Suplita RL; Farthing JN; Gutierrez T; Hohmann AG
Neuropharmacology; 2005 Dec; 49(8):1201-9. PubMed ID: 16129456
[TBL] [Abstract][Full Text] [Related]
34. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study.
Rubino T; Massi P; Patrini G; Venier I; Giagnoni G; Parolaro D
Neuroreport; 1994 Dec; 5(18):2493-6. PubMed ID: 7696588
[TBL] [Abstract][Full Text] [Related]
35. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
36. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.
Freedland CS; Whitlow CT; Smith HR; Porrino LJ
Brain Res; 2003 Feb; 962(1-2):169-79. PubMed ID: 12543468
[TBL] [Abstract][Full Text] [Related]
37. In vitro reinforcement of hippocampal bursting by the cannabinoid receptor agonist (-)-CP-55,940.
Xue BG; Belluzzi JD; Stein L
Brain Res; 1993 Oct; 626(1-2):272-7. PubMed ID: 8281436
[TBL] [Abstract][Full Text] [Related]
38. The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain.
Arnold JC; Topple AN; Mallet PE; Hunt GE; McGregor IS
Brain Res; 2001 Dec; 921(1-2):240-55. PubMed ID: 11720732
[TBL] [Abstract][Full Text] [Related]
39. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats.
Serra S; Carai MA; Brunetti G; Gomez R; Melis S; Vacca G; Colombo G; Gessa GL
Eur J Pharmacol; 2001 Nov; 430(2-3):369-71. PubMed ID: 11711056
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.
Viganò D; Rubino T; Vaccani A; Bianchessi S; Marmorato P; Castiglioni C; Parolaro D
Psychopharmacology (Berl); 2005 Nov; 182(4):527-36. PubMed ID: 16079992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
